Information about the tumor genotype, and in particular about mutations in PI3K/AKT, KRAS and BRAF are currently used to predict the success of systemic chemotherapy of different types of tumors and are used to stratify patients for treatment options for example in colon cancer [16]. This evidence concerns the gene BRAF and neoplasm.